A toxicity profile of osteoprotegerin in the cynomolgus monkey.
The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Osteoprotegerin (OPG) is a novel secreted glycoprotein of the tumor necrosis factor (TNF) receptor superfamily that acts as an antiresorptive agent inhibiting osteoclast maturation. OPG acts by competitively inhibiting the association of the OPG ligand with the RANK receptor on osteoclasts and osteoclast precursors. This inhibition of osteoclasts can lead to excess accumulation of newly synthesized bone and cartilage in vivo. The purpose of this study was to investigate the potential toxicity of a human recombinant form of OPG in the young cynomolgus monkey. OPG was administered by intravenous (IV) or subcutaneous (SC) injection three times per week for either 4 or 13 weeks. There were no deaths during the study, no clinical signs related to treatment, no effect on body weight, appetence, or ophthalmology. No toxicologically relevant changes in routine laboratory investigations, organ weights, or gross or histopathological findings were observed. Serum ionized calcium and phosphorus were decreased at all dose levels. Evaluations were performed to monitor biochemical markers of bone resorption ( N-telopeptide [NTx], deoxypyridinoline [DPD]), bone formation (skeletal alkaline phosphatase [s ALP], osteocalcin [OC]), parathyroid hormone [PTH], and bone density of the proximal tibia and distal radius in vivo. Dose-related decreases in NTx and/or DPD were observed at each dose level, with up to a 90% decrease in NTx noted for animals treated IV or SC at 15 mg/kg. Similar decreases were observed for s ALP and OC. PTH was increased for animals treated at 5 and 15 mg/kg (IV or SC). Trabecular bone density was increased for the majority of males and females treated IV or SC at 15 mg/kg and males treated IV at 5 mg/kg. Microscopic examination of the sternebrae revealed corresponding increases in bone. Decreases in markers of bone turnover, and corresponding increases in bone density, were consistent with the pharmacological action of OPG as an osteoclast inhibitor. The no-observable-adverse-effect level (NOAEL) of OPG was 15 mg/kg.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In young gonad-intact cynomolgus monkeys, 3 months of OPG treatment (25 mg/kg sc injections once monthly) led to significant reductions in biochemical markers of bone turnover, including serum alkaline phosphatase and urinary N-telopeptide (uNTX) (22).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [22]
In the citing paper
“There were no treatmentrelated clinical observations and no treatment-related histopathological findings in animals treated for 1 or 3 months with OPG (22).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [22]
In the citing paper
“No clinical signs of hypocalcemia were noted in this toxicology study, perhaps due to an observed OPG-related increase in serum PTH that maintained serum calcium at an asymptomatic level.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [22]
In the citing paper
“OPG treatment increased BMD and bone mineral content (BMC) in the proximal tibia and distal radius.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [22]
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationOsteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483 · cited 2×
“Previous in vivo studies in transgenic OPG −/− mice show early onset of osteoporosis (Bucay et al. 1998), whereas transgenic mice overexpressing OPG exhibit osteopetrosis due to the lack of remodeling by osteoclasts (Simonet et al.”
BackgroundSelf-citationLi, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119 · cited 2×
“OPG acts by competitively inhibiting the association of the OPG ligand with the RANK receptor on osteoclasts and osteoclast precursors.”
BackgroundSelf-citationModulation of Osteoclast Differentiation
SUDA, T., TAKAHASHI, N., & MARTIN, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · cited 4×
“OPG acts by competitively inhibiting the association of the OPG ligand with the RANK receptor on osteoclasts and osteoclast precursors.”
BackgroundSelf-citationModulation of osteoclast differentiation by local factors
Suda, T., Udagawa, N., Nakamura, I., Miyaura, C., & Takahashi, N. (1995) · Bone · doi:10.1016/8756-3282(95)00185-g · Cited by 321
Ferretti, J. L., Capozza, R. F., & Zanchetta, J. R. (1996) · Bone · doi:10.1016/8756-3282(95)00438-6 · Cited by 264
Takahashi, N., Udagawa, N., Takami, M., & Suda, T. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1/50109-8 · Cited by 162
Assessing bone quantity by pQCT
Gasser, J. A. (1995) · Bone · doi:10.1016/8756-3282(95)00287-n · Cited by 146 · cited 2×
“Previous studies in mice (Breen et al. 1998) and rats (Breen et al. 1996; Ferretti, Capozza, and Zanchetta 1996; Gasser 1996; Rosen, Tollin, and Balena 1995; Sato et al. 1995) have investigated the precision of pQCT in long bones and have documented its use in examining therapeutic effects of…”
BackgroundSato, M., Kim, J., Short, L. L., Slemenda, C. W., & Bryant, H. U. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24554-2 · Cited by 119
Jerome, C. P., Carlson, C. S., Register, T. C., Bain, F. T., Jayo, M. J., Weaver, D. S., & Adams, M. R. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090413 · Cited by 114 · cited 2×
“The cynomolgus monkey is often used as a model of human skeletal conditions due to similarities in increased bone turnover (Jerome et al. 1994) and bone loss (Longscope et al.”
BackgroundThe Osteoporotic Syndrome: Detection, Prevention, and Treatment.
(1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-4-629_3 · Cited by 108
Nonhuman primate models in skeletal research
Jerome, C. P., & Peterson, P. E. (2001) · Bone · doi:10.1016/s8756-3282(01)00477-x · Cited by 94
Rosen, H. N., Tollin, S. R., Balena, R., Middlebrooks, V. L., Beamer, W. G., Donohue, L. R., Rosen, C. J., Turner, A. S., Holick, M. F., & Greenspan, S. L. (1995) · Calcified Tissue International · doi:10.1007/bf00298994 · Cited by 94
Bone mass in female cynomolgus macaques: A cross-sectional and longitudinal study by age
Jayo, M. J., Jerome, C. P., Lees, C. J., Rankin, S. E., & Weaver, D. S. (1994) · Calcified Tissue International · doi:10.1007/bf00301684 · Cited by 91 · cited 2×
“In cynomolgus monkeys, peak bone mass appears to be achieved by 9 years of age by densitometry data and epiphysial growth plate closure by around 6 years of age (Jayo et al. 1994).”
BackgroundEffects of ovariectomy on vertebral trabecular bone in the cynomolgus monkey (Macaca fascicularis)
Miller, L. C., Weaver, D. S., McAlister, J. A., & Koritnik, D. R. (1986) · Calcified Tissue International · doi:10.1007/bf02556597 · Cited by 58
The effect of ovariectomy on spine bone mineral density in rhesus monkeys
Longcope, C., Hoberg, L. M., Steuterman, S., & Baran, D. T. (1989) · Bone · doi:10.1016/8756-3282(89)90130-0 · Cited by 50 · cited 2×
“1994) and bone loss (Longscope et al. 1989) in association with estrogen depletion.”
BackgroundThe effects of androgens on the mechanical properties of primate bone
Kasra, M., & Grynpas, M. D. (1995) · Bone · doi:10.1016/8756-3282(95)00211-u · Cited by 50
Jayo, M. J., Rankin, S. E., Weaver, D. S., Carlson, C. S., & Clarkson, T. B. (1991) · Calcified Tissue International · doi:10.1007/bf02555858 · Cited by 47
Breen, S. A., Millest, A. J., Loveday, B. E., Johnstone, D., & Waterton, J. C. (1996) · Calcified Tissue International · doi:10.1007/bf02509446 · Cited by 45
Changes in Bone Mass and Bone Biomarkers of Cynomolgus Monkeys during Pregnancy and Lactation1
Lees, C. J., Jerome, C. P., Register, T. C., & Carlson, C. S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.12.5344 · Cited by 37 · cited 1×
“Previous studies have been performed in cynomolgus monkeys to elucidate the bone loss observed in diseases such as osteoporosis (Jayo et al. 1991, 1994; Kasra and Grynpas 1995; Lees et al. 1998; Lundon, Dumitriu, and Grynpas 1997; Lundon and Grynpas 1993; Miller et al. 1986).”
BackgroundHotchkiss, C. E. (1999) · Bone · doi:10.1016/s8756-3282(98)00152-5 · Cited by 31 · cited 1×
“Successful use of pQCT analysis in cynomolgus monkeys has also been documented (Hotchkiss 1999).”
MethodLundon, K., & Grynpas, M. D. (1993) · Bone · doi:10.1016/8756-3282(93)90169-b · Cited by 31
Breen, S. A., Loveday, B. E., Millest, A. J., & Waterton, J. C. (1998) · Laboratory Animals · doi:10.1258/002367798780599839 · Cited by 23 · cited 2×
“Previous studies in mice (Breen et al. 1998) and rats (Breen et al. 1996; Ferretti, Capozza, and Zanchetta 1996; Gasser 1996; Rosen, Tollin, and Balena 1995; Sato et al. 1995) have investigated the precision of pQCT in long bones and have documented its use in examining therapeutic effects of…”
BackgroundBIOCHEMICAL MARKERS OF BONE TURNOVER
Rosalki, S. (1998) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1998.tb11620.x · Cited by 23 · cited 2×
“Deoxypyridinoline is a specific marker of bone resorption and is solely derived from bone collagen (Garnero and Delmas 1997; Rosalki 1998).”
BackgroundGarnero, P., & Delmas, P. D. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70287-5 · Cited by 22
The osteoporotic syndrome: Detection, prevention, and treatment
Licata, A. A. (1993) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(93)90130-7 · Cited by 21
Lundon, K., Dumitriu, M., & Grynpas, M. D. (1997) · Calcified Tissue International · doi:10.1007/s002239900186 · Cited by 12
Millest, A. J., Breen, S. A., Loveday, B. E., Clarkson, P. N., Simpson, C. A., Waterton, J. C., & Johnstone, D. (1997) · Bone · doi:10.1016/s8756-3282(97)00014-8 · Cited by 12 · cited 2×
“1995) have investigated the precision of pQCT in long bones and have documented its use in examining therapeutic effects of antiresorptive agents in the rat (Millest et al. 1997).”
Background
Research works printed but not linked: 2
- Breen, S. A., 1996, Calcified Tissue Int., 58, 449
- Lees, C. J., 1998, J. Clin. Endocrinol. Metab., 83, 4298
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
Szulc, P., Seeman, E., Duboeuf, F., Sornay-Rendu, E., & Delmas, P. D. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060904 · Cited by 240
“tegerin increased periosteal bone formation rate and periosteal diameter in rats and monkeys.((37,38)) The monoclonal”
BackgroundInternal inflammatory root resorption: the unknown resorption of the tooth
HAAPASALO, M., & ENDAL, U. (2006) · Endodontic Topics · doi:10.1111/j.1601-1546.2008.00226.x · Cited by 170
Metadata
- Authors
- Smith, B. B., Cosenza, M. E., Mancini, A., Dunstan, C., Gregson, R., Martin, S. W., Smith, S. Y., & Davis, H.
- Affiliations
- Amgen (United States) (US)
- Clin Trials Bio Research Ltd., Montreal, Quebec, Canada
- ORCID
- Dunstan, Colin
- Venue
- International Journal of Toxicology
- Publisher
- SAGE Publications
- Published
- 2003-09
- Volume
- 22
- Issue
- 5
- Pages
- 403-412
- ISSN
- 1091-5818 (ISSN-L)
- 1092-874X
- OpenAlex
- W2083816793
- Cited by
- 33
- References
- 30
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 2 · 2013: 1 · 2012: 2
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- International Journal of Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoprotegerin, toxicity, Macaca fascicularis, osteoclast inhibition, RANK ligand, antiresorptive agents, bone turnover markers, bone mineral density, parathyroid hormone, no-observed-adverse-effect level, dose-limiting toxicity, intravenous administration, subcutaneous administration
- MeSH terms
- Amino Acids, Animals, Bone Resorption, Collagen, Dose-Response Relationship, Drug, Female, Glycoproteins, Humans, Injections, Intravenous, Injections, Subcutaneous, Macaca fascicularis, Male, Parathyroid Hormone, Peptides, Radius, Recombinant Proteins, Tibia, Biomarkers, Absorptiometry, Photon, Bone Density, Osteocalcin, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, No-Observed-Adverse-Effect Level, Collagen Type I, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.